Different iron pill schedules for anemia in kidney disease
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests different ways of taking iron pills to treat iron-deficiency anemia in people with chronic kidney disease (stages 2, 3, or 4). It aims to find the best dosing schedule that works and is easy to follow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic kidney disease (CKD) at stage 2, 3, or 4.
- You have iron-deficiency anemia.
- You are not on dialysis and your kidney function is not extremely low (eGFR above 15).
- You have not had a blood transfusion in the last 3 months.
- You are not pregnant.
- You do not have hemolytic anemia, liver disease, autoimmune disease, cancer, or polycystic kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking iron by mouth can improve iron levels and anemia (low red blood cell counts) in children with chronic kidney disease. It may help reduce fatigue and support normal blood-making, by comparing different approaches for children who meet specific iron test results.
This trial tests whether taking iron pills every other day works as well as taking them every day. It is for people with iron deficiency anemia who have not used iron recently.
This Phase 2 study tests ferric citrate, a medicine that helps control phosphate and iron balance, in children with chronic kidney disease. It may help slow problems related to kidney disease by improving lab measures like phosphate levels.
This study compares two IV iron treatments—ferumoxytol and iron sucrose—to treat iron deficiency anemia in children with chronic kidney disease. It aims to see which option works better and is safe, and also to learn how each medicine behaves in the body.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests whether a new blood test (reticulocyte hemoglobin) is better than the usual iron test (transferrin saturation) for guiding when to give iron to people on dialysis. If you have anemia (low red blood cells) from kidney disease, this study may help doctors find the best way to treat your iron levels.
Hear when a new CKD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.